Grand Pharmaceutical Group (HKG:0512) completed the first patient enrollment and dosing in China for the international multi-center Phase III clinical trial of ITM-11, an innovative radionuclide-drug conjugate.
The medicine ITM-11 is meant to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs), according to a Wednesday filing with the Hong Kong bourse.
The drug is designed for patients with moderate to aggressive forms (Grade 2 and Grade 3) of these tumors, which have a specific protein called somatostatin receptor (SSTR+).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.